Mustang Bio Inc (MBIO) Price-to-Projected Revenue Ratio
Mustang Bio, Inc. (MBIO) is optimizing capital through university partnerships in the development of CAR-T therapies. The projected P/S ratio visualizes market expectations, where reflects the current value of the metric. A team of top biologists is advancing genetic engineering, driven by strong financial incentives. Proprietary patents and stringent FDA requirements create an insurmountable barrier to entry for new players in the sector.
Mustang Bio - analytical breakdowns and key metrics (MBIO)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt and liquidity data:
- net income and valuation multiples indicators:
MBIO - Company Net Income|Projected Future Earnings Mustang Bio, Inc.|MBIO - Business Payback Period|Future Price to Earnings Mustang Bio|MBIO - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Mustang Bio Corp|MBIO - Operating profit before amortization|Earnings per share for the last twelve months Mustang Bio|MBIO - Earnings per share for the last 12 months|Quarterly EPS earnings growth mustangbio.com|MBIO - Earnings growth in current year|Net earnings per share growth forecast for next year Mustang Bio, Inc.
- company sales and revenue statistics:
Analysis of all company metrics:Mustang Bio Inc (MBIO)
For Mustang Bio, Inc. (MBIO), which develops radical CAR-T therapies for oncology, valuation is based on expectations of future commercial success. By analyzing forward P/S changes on GURU.Markets, an investor can view the ratio of current market capitalization to projected revenue, making it possible to determine the asset's degree of overheating relative to industry trends and avoid the risks of unjustifiably inflated multiples when buying.
Analysis of competing companies
Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward Price-to-Revenue Multiple PRME (Prime Medicine Bio)|Market Cap to Expected Sales Ratio Taysha|uniQure Pharma - Forward Price-to-Revenue Multiple|MeiraGTx Holdings plc - Price-to-Projected Revenue Ratio|regenxbio.com - Forward P/S Multiple|Solid Bio (SLDB) - Forward Price-to-Revenue Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Therapeutics)|Forward P/S Multiple RCKT|Price-to-Projected Revenue Ratio FDMT (4D Molecular Therapeutics Inc)|Forward P/S Multiple LXEO (Lexeo Therapeutics Inc.)|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Price-to-Projected Revenue Ratio|Codexis Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Sangamo BioSciences|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology)|Price-to-Projected Revenue Ratio metagenomi.co (MGX)|DTIL: Future Price to Revenue|Price-to-Projected Revenue Ratio Generation Bio Co. GBIO|BOLD: Market Cap to Projected Revenue|XCUR: Forward Price-to-Revenue Multiple|Imunon (IMNN) - Forward Price-to-Revenue Multiple|PHIO (RXi Pharmaceuticals) - Forward Price-to-Revenue Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.
